We are live on
!
Find out more
FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$3.89B
1-Year Est. Return
201.1%
This Fund
S&P 500
This Quarter
Est. Return
+34.04%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.89B
AUM Growth
+$163M
(+4.4%)
Cap. Flow
+$27.4M
Cap. Flow
% of AUM
0.71%
Top 10 Holdings %
Top 10 Hldgs %
73.49%
Holding
43
New
3
Increased
8
Reduced
10
Closed
5
Top Buys
| 1 |
Mirum Pharmaceuticals
MIRM
|
+$83.2M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$31.1M |
| 3 |
Erasca
ERAS
|
+$23M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$19.1M |
| 5 |
PVLA
Palvella Therapeutics
PVLA
|
+$16.7M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$70.9M |
| 2 |
ABVX
Abivax
ABVX
|
+$51M |
| 3 |
RAPT
RAPT Therapeutics
RAPT
|
+$33.3M |
| 4 |
Revolution Medicines
RVMD
|
+$12.3M |
| 5 |
Travere Therapeutics
TVTX
|
+$9.23M |
Sector Composition
| 1 | Healthcare | 99.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lexeo Therapeutics
LXEO
$358M
| $25.4M | 0.65% |
4,424,725
| – | – |
|
27
Alkermes
ALKS
$8.66B
| $24.8M | 0.64% |
700,647
| – | – |
|
28
Aclaris Therapeutics
ACRS
$749M
| $18.5M | 0.48% |
+4,925,374
| New | +$16.6M |
|
|
29
Monte Rosa Therapeutics
GLUE
$1.96B
| $16.4M | 0.42% |
+1,000,000
| New | +$19.1M |
|
30
Immunocore
IMCR
$1.75B
| $14.6M | 0.38% |
484,782
+100,000
| +26% | +$3.24M |
|
31
MannKind Corp
MNKD
$1.25B
| $14.5M | 0.37% |
5,900,000
+1,675,000
| +40% | +$7.47M |
|
|
VALN
32
Valneva
VALN
$519M
| $14.3M | 0.37% |
2,291,666
| – | – |
|
33
Evolus
EOLS
$371M
| $10.8M | 0.28% |
2,630,665
| – | – |
|
34
NewAmsterdam Pharma Warrant
NAMSW
$94.6M
| $10M | 0.26% |
500,333
| – | – |
|
35
Allogene Therapeutics
ALLO
$618M
| $9.26M | 0.24% |
3,796,668
-72,082
| -2% | -$144K |
|
|
AUTL
36
Autolus Therapeutics
AUTL
$389M
| $6.14M | 0.16% |
4,447,910
-175,414
| -4% | -$266K |
|
37
iBio
IBIO
$67.1M
| $3.71M | 0.1% |
1,953,467
| – | – |
|
38
Xilio Therapeutics
XLO
$59.4M
| $3.55M | 0.09% |
422,505
-2
| -0% | -$16 |
|
|
ABVX
39
Abivax
ABVX
$12B
| – | – |
-378,300
| Closed | -$51M |
|
40
Design Therapeutics
DSGN
$788M
| – | – |
-521,000
| Closed | -$4.89M |
|
|
RAPT
41
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-983,333
| Closed | -$33.3M |
|
|
RNAM
42
DELISTED
Avidity Biosciences
RNAM
| – | – |
-983,125
| Closed | -$70.9M |
|
|
43
Travere Therapeutics
TVTX
$5.14B
| – | – |
-241,592
| Closed | -$9.23M |
|
Similar funds
GAMH
MSI
CCM
TFM
SCM
MIM
AA
DACG